Glenmark Pharmaceuticals Limited - History, Latest Updates, Milestones, Subsidiaries & Share Price

Glenmark Pharmaceuticals Limited - Company Overview

Glenmark Pharmaceuticals Limited is a leading global pharmaceutical company founded in 1977. Headquartered in Mumbai, India, the company has built a strong presence across branded formulations, generics, specialty medicines, and active pharmaceutical ingredients (APIs). Glenmark operates in over 80 countries and focuses on key therapeutic areas such as respiratory, dermatology, oncology, and cardiovascular health.

The company is widely recognized for its emphasis on research, innovation, and expanding global healthcare access through quality medicines. With manufacturing facilities and research centres across multiple regions, Glenmark continues to strengthen its footprint in domestic and international markets . Many investors track strong healthcare businesses like Glenmark through trusted stock brokers in India to stay updated on long-term opportunities.

Glenmark Pharmaceuticals Limited Moves In 2026

• March 19, 2026: Glenmark Pharmaceuticals’ wholly-owned subsidiary, Glenmark Pharmaceuticals Inc., USA, launched Milnacipran Hydrochloride Tablets in strengths of 12.5 mg, 25 mg, 50 mg, and 100 mg in the United States. According to IQVIA data, the reference market recorded annual sales of approximately $102.9 million for the 12-month period ended January 2026.

• March 23, 2026: Glenmark Pharmaceuticals introduced GLIPIQ (semaglutide) in India for the treatment of Type 2 Diabetes Mellitus. The launch aims to improve affordability and expand patient access to advanced GLP-1 therapy, enabling earlier diabetes treatment adoption.

• April 9, 2026: Glenmark Pharmaceuticals received final approval from the USFDA for Progesterone Vaginal Inserts, 100 mg. The product was found bioequivalent and therapeutically equivalent to Endometrin Vaginal Inserts of Ferring Pharmaceuticals Inc. It will be marketed in the U.S. through Glenmark Pharmaceuticals Inc., USA. Based on IQVIA data, the reference product market generated annual sales of nearly $59.2 million for the 12 months ended February 2026.
  
  

Glenmark Pharmaceuticals Limited Moves In 2025

January 2025

Introduced Vancomycin Hydrochloride Injection to the U.S. pharmaceutical market as part of its expanding product portfolio.

February 2025

Posted robust top-line revenue growth and better EBITDA margin for Q3 FY2025.

March 2025

Expanded its cardiometabolic treatment portfolio with the introduction of Empagliflozin in the Indian pharmaceutical market, enhancing its diabetes care offerings.

April 2025

Glenmark Pharmaceuticals Inc. initiated sales of Mixed Amphetamines Immediate-Release Tablets in the U.S.

May 2025

Board meeting to consider quarterly financial performance.

 

Glenmark Pharmaceuticals Ltd Share Price Performance

In May 2025, the Glenmark share price settled at Rs.1,381.70, reflecting a slight increase compared to April 2025, indicating steady market performance.

By April 2025, the Glenmark share price was at Rs.1,360.70, with minimal movements in market trends.

In March 2025, the Glenmark share price closed at Rs.1,412.50, which is a significant hike compared to February.

Throughout February 2025, the Glenmark share price settled at Rs.1,390.80, registering stability in its performance.

On January 2025, the closing price of Glenmark share was Rs.1,368.80, representing steady movement in the beginning of the year.
The Glenmark share price of Rs.1,342.40 as of December 2024 shows slight volatility when the year ended.

In November 2024, the Glenmark share price closed at Rs.1,356.80, reflecting a steady upward movement in the market.

On October 2024, the Glenmark share price closed at Rs.1,376.90, which is a reflection of positive market sentiments.

In September 2024, the Glenmark share price was at Rs.1,378.10, tending steadily.

As of August 2024, the Glenmark share price was Rs.1,376.30, showing very little fluctuation from last month.

In July 2024, the Glenmark share price closed at Rs.1,384.40, showing strength in terms of share movement.

In June 2024, the Glenmark share price closed at Rs.1,407.60, which was one of the better performances in the past year.

 

Evolution Of Glenmark Pharmaceuticals Limited: From Past to Present

1977-1999: Foundation & Early Growth

1977: Gracias Saldanha founded Glenmark Pharmaceuticals, with an emphasis on generic pharmaceuticals and active pharmaceutical ingredients (APIs).

1979: Forayed into the dermatology division with the introduction of Candid Cream, its first major product success.

1983: Commissioned its first manufacturing facility at Nasik, Maharashtra, to strengthen its production capabilities.

1989: Extended operations outside India, operating in Afghanistan, Sri Lanka, Kenya, and Mauritius.

1999: Went public on the Bombay Stock Exchange (BSE), utilizing proceeds to construct its first research center.

2000-2010: Global Expansion & Market Entry

2000: Listed on the National Stock Exchange (NSE), boosting investor involvement.

2001: Started API manufacturing business, diversifying into bulk drug manufacturing.

2004: Executed its first out-licensing agreement with Forest Laboratories for the GRC 3886 molecule, receiving $35 million.

2005: Entered the Japanese market with a licensing agreement with Teijin Pharma.

2006: Opened an R&D center in Switzerland to develop biologics.

2008: Became India's fifth-largest pharma company, with robust revenue growth.

2010: Strengthened its oncology research to lay the foundation for future breakthroughs.

2011-2020: Innovation & Specialty Medicines

2011: Registered $778 million of global sales, led by its foray into U.S. and European generics market.

2014: Entered an out-licensing agreement with Forest Labs for its mPGES-1 Inhibitor molecule, for which it received $15 million.

2016: Discovered GBR 1372, a bispecific monoclonal antibody oncology indication. 

2017: Launched first generic equivalent of Zetia in the U.S., Ezetimibe, boosting cardiovascular portfolio. 

2019: Established Glenmark Life Sciences to focus on high-value APIs.

2021-2025: Building Strength in Oncology & Research

2021: Expanded its pipeline of oncology indications, specifically for hematological malignancies and solid tumors. 

2022: FDA approval of Ryaltris Nasal Spray marked a major development in the field of respiratory therapies.

2024: Set up Ichnos Glenmark Innovation (IGI), speeding up cancer drug development.

2025: Introduced Mixed Amphetamines Immediate-Release Tablets, broadening its neurology portfolio.

Glenmark Pharmaceuticals has transformed from a generic drug company to a worldwide leader in specialty pharmaceuticals, constantly innovating in oncology, respiratory, and dermatology therapies.

 

Glenmark Pharmaceuticals Limited Information

 

Inside Glenmark Pharmaceuticals Limited

Rolled out Mixed Amphetamines Immediate-Release Tablets.
Glenmark Pharmaceuticals successfully obtained regulatory approval for its Olopatadine Hydrochloride Ophthalmic Solution, enabling its market entry in the United States . U.S. FDA inspected Glenmark's Indore manufacturing facility.

Glenmark share price NSE

Company Name	Sector	Share Price Link
Glenmark Pharmaceuticals Limited	Pharmaceuticals	Glenmark share Price

Many investors use a secure trading account to monitor pharma stocks, place trades, and build diversified portfolios efficiently.

Conclusion

Glenmark Pharmaceuticals Limited continues to strengthen its market position through innovation, research capabilities, and expanding global operations. Its focus on specialty therapies, branded products, and international growth makes it a company closely watched by long-term investors.

As healthcare demand rises globally, Glenmark remains well-placed to benefit from sector growth and product diversification.
Begin your investment journey with Enrich Money — a reliable platform built to support smart investing. Whether you are starting small or building wealth steadily, explore opportunities through a 10 rs investment trading app designed for modern investors.

 

Frequently Asked Questions

What is the glen pharma share price?

The Glenmark life share price can be found on Enrich Money.

How do I monitor Glenmark pharma stock price?

Glenmark share price can be found on Enrich Money

Where can I find the Glenmark share price on NSE?

You can look for the Glenmark share price NSE official website or on Enrich Money

What is Glenmark share price BSE?

Glenmark share price can be accessed on the BSE official website or Enrich Money

How has Glenmark share price performed this year? 

The Glenmark share price has varied between Rs.1,336.00 and Rs.1,450.60 in 2025.

Disclaimer:  This blog is dedicated exclusively for educational purposes. Please note that the securities and investments mentioned here are provided for informative purposes only and should not be construed as recommendations. Kindly ensure thorough research prior to making any investment decisions. Participation in the securities market carries inherent risks, and it's important to carefully review all associated documents before committing to investments. Please be aware that the attainment of investment objectives is not guaranteed. It's important to note that the past performance of securities and instruments does not reliably predict future performance.